Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival.
Teun B M van den HeuvelRobin J LurvinkKoen P B RoversIrene E G van HellemondIgnace H J T de HinghPublished in: Journal of surgical oncology (2024)
In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6-trial.
Keyphrases
- systematic review
- locally advanced
- rectal cancer
- meta analyses
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- minimally invasive
- radiation therapy
- randomized controlled trial
- ejection fraction
- early stage
- peritoneal dialysis
- clinical trial
- lymph node
- cross sectional
- patient reported outcomes
- drug induced
- case control